Mortality in Patients With Septic Shock by Multidrug Resistant Bacteria Risk Factors and Impact of Sepsis Treatments

被引:40
作者
Busani, Stefano [1 ]
Serafini, Giulia [1 ]
Mantovani, Elena [1 ]
Venturelli, Claudia [2 ]
Giannella, Maddalena [3 ]
Viale, Pierluigi [3 ]
Mussini, Cristina [4 ]
Cossarizza, Andrea [5 ]
Girardis, Massimo [1 ]
机构
[1] Azienda Osped Univ Policlin, Cattedra & Struttura Anestesia & Rianimaz, Modena, Italy
[2] Azienda Osped Univ Policlin, Dipartimento Interaziendale Integrato Med Lab & A, Modena, Italy
[3] Univ Bologna, Clin Malattie Infett, Dipartimento Sci Med & Chirurg, Bologna, Italy
[4] Univ Modena & Reggio Emilia, Dipartimento Attiv Integrata Med Med Urgenza & Sp, Malattie Infett, Modena, Italy
[5] Univ Modena & Reggio Emilia, Dipartimento Chirurg Med Odontoiatria & Sci Morfo, Modena, Italy
关键词
septic shock; multidrug resistant bacteria; sepsis bundle treatment; host immune response; INTRAVENOUS IMMUNOGLOBULIN; ACINETOBACTER-BAUMANNII; INFECTIONS; THERAPY; METAANALYSIS; PREDICTORS; MECHANISMS; SCORE;
D O I
10.1177/0885066616688165
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Patients with septic shock by multidrug resistant (MDR) microorganism maybe considered a specific population of critical patients at very high risk of death in whom the effects of standard sepsis treatment has never been assessed. The objective of this retrospective analysis was to evaluate the risk factors for 30-day mortality and the impact of sepsis management in patients with septic shock caused by MDR bacteria. Methods: Patients with septic shock by MDR bacteria admitted to the mixed intensive care unit (ICU) of Modena University Hospital during a 6-year period were studied. The clinical and microbiological characteristics and sepsis treatments provided were analyzed and compared between survivors (S) and nonsurvivors (NS) at 30 days after septic shock appearance. Results: Ninety-four patients were studied. All therapeutic interventions applied to patients during their ICU stay did not show statistical significance between S and NS groups, except for administration of immunoglobulin M (IgM) preparation which were provided more frequently in S group (P < .05). At the multivariate adjusted analysis, preexisting cancer (odds ratio [OR] = 2.965) and Acinetobacter baumannii infections (OR = 3.197) were independently correlated with an increased risk of 30-day mortality, whereas treatment with IgM preparation was protective (OR = 0.283). Conclusions: This retrospective study showed that in patients with septic shock caused by MDR bacteria, history of cancer and infection sustained by A baumannii increase the risk of mortality and that standard sepsis treatments do not seem to provide any protective effect. Adjunctive therapy with IgM preparation seems to be beneficial, but further appropriate studies are needed to confirm the results observed.
引用
收藏
页码:48 / 54
页数:7
相关论文
共 27 条
[1]  
Busani S, 2016, MINERVA ANESTESIOL, V82, P559
[2]   Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock [J].
Cavazzuti, Ilaria ;
Serafini, Giulia ;
Busani, Stefano ;
Rinaldi, Laura ;
Biagioni, Emanuela ;
Buoncristiano, Marta ;
Girardis, Massimo .
INTENSIVE CARE MEDICINE, 2014, 40 (12) :1888-1896
[3]   Metallo-β-lactamases: a last frontier for β-lactams? [J].
Cornaglia, Giuseppe ;
Giamarellou, Helen ;
Rossolini, Gian Maria .
LANCET INFECTIOUS DISEASES, 2011, 11 (05) :381-393
[4]   Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients [J].
Fukuta, Yuriko ;
Muder, Robert R. ;
Agha, Mounzer E. ;
Clarke, Lloyd G. ;
Wagener, Marilyn M. ;
Hensler, Amelia M. ;
Doi, Yohei .
AMERICAN JOURNAL OF INFECTION CONTROL, 2013, 41 (12) :1249-1252
[5]   Task force on management and prevention of Acinetobacter baumannii infections in the ICU [J].
Garnacho-Montero, Jose ;
Dimopoulos, George ;
Poulakou, Garyphallia ;
Akova, Murat ;
Miguel Cisneros, Jose ;
De Waele, Jan ;
Petrosillo, Nicola ;
Seifert, Harald ;
Timsit, Jean Francois ;
Vila, Jordi ;
Zahar, Jean-Ralph ;
Bassetti, Matteo .
INTENSIVE CARE MEDICINE, 2015, 41 (12) :2057-2075
[6]   Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins [J].
Giamarellos-Bourboulis, E. J. ;
Tziolos, N. ;
Routsi, C. ;
Katsenos, C. ;
Tsangaris, I. ;
Pneumatikos, I. ;
Vlachogiannis, G. ;
Theodorou, V. ;
Prekates, A. ;
Antypa, E. ;
Koulouras, V. ;
Kapravelos, N. ;
Gogos, C. ;
Antoniadou, E. ;
Mandragos, K. ;
Armaganidis, A. .
CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (06) :499-506
[7]   Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome [J].
Gudiol, Carlota ;
Calatayud, Laura ;
Garcia-Vidal, Carolina ;
Lora-Tamayo, Jaime ;
Cisnal, Maria ;
Duarte, Rafael ;
Arnan, Montserrat ;
Marin, Mar ;
Carratala, Jordi ;
Gudiol, Francesc .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (02) :333-341
[8]  
Hamers L, 2015, MINERVA ANESTESIOL, V81, P426
[9]   Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach [J].
Hotchkiss, Richard S. ;
Monneret, Guillaume ;
Payen, Didier .
LANCET INFECTIOUS DISEASES, 2013, 13 (03) :260-268
[10]   Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock [J].
Kreyrnann, K. Georg ;
de Heer, Geraldine ;
Nierhaus, Axel ;
Kluge, Stefan .
CRITICAL CARE MEDICINE, 2007, 35 (12) :2677-2685